Further, increased IL-6 levels after TKI treatment and subsequent inhibition of the IL-6 signaling pathway enhanced efficacy of sorafenib, another TKI that blocks VEGF and PDGF receptors, which is approved for advanced RCC [43] on suppressing angiogenesis and tumor growth [44]. Here, VEGFA is linked to neoplasm.